Up to 80% of people’s health outcomes are influenced by non-clinical factors, however, most life sciences organizations lack a way of quantifying and understanding how they impact patient outcomes. Join industry leaders for a webinar to learn more about resources to help life sciences organizations better understand risk exposure for the communities and patients they serve.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Event Overview:
Up to 80% of people’s health outcomes are influenced by non-clinical factors such as economic
strain, food insecurity, health literacy, transportation barriers. These non-clinical factors can
dramatically impact areas like disease and treatment awareness, medication adherence, clinical
trial recruitment and more. Most life sciences organizations lack a way of quantifying and
understanding the wide array of factors beyond clinical care impacting patient outcomes.
Traditional social determinants of health (SDOH) data points alone do not provide the insights to
develop a clear, actionable patient profile to achieve equitable care.
Join industry leaders for a webinar to:
Key Learning Objectives:
- Discuss resources that can help your organization better understand risk exposure for the communities and patients you serve.
- Avoid strategies that systematically miss the most vulnerable communities, cohorts and patients.
- Leverage data to inform action across different therapeutic areas such as oncology and diabetes.
Who Should Attend:
Life Sciences Companies
Titles: Market Access, Payer Strategy, Access Strategy, Market Insights, Reimbursement, RWE, brand marketing, brand development, brand strategy, brand product marketing, commercialization, marketing and communications, analytics, health equity, HEOR
Speakers
Trenor Williams, MD
Co-founder and CEO
Socially Determined
Dr. Trenor Williams is a family physician, entrepreneur, former health system executive and consulting leader, past founder and CEO of Clinovations which he sold to the Advisory Board Company in 2014, and current CEO and CO-founder of Socially Determined. In 2017, Dr. Williams co-founded Socially Determined in order to create an analytics platform that integrates the social determinants of health with clinical and claims data in order to quantify and visualize social risk and the specific impacts on health and healthcare outcomes. With more than 20 years of healthcare experience, Dr. Williams’ unique perspective is formed at the intersection of healthcare and technology. He has an extensive understanding and knowledge in the implementation of healthcare technology, health plan market growth and SDOH strategy development for leading healthcare stakeholders here in the United States and around the world.
Mikki Nasch
Co-founder
Evidation Health
Mikki Nasch is focused on working to improve the patient experience. She is the former co-founder and head of business development at Evidation Health. Prior to Evidation, Mikki co-founded and led business activities at The Activity Exchange. Previously, Mikki was on the founding team of Sense Networks (exited to YP.com) and served as EVP of Business Development. Mikki has been the Vice President of Market Management at FairIsaac, Inc. (NYSE: FIC), held leadership positions in the incubation phase of numerous startups, and led development of products, sales strategies, business models and corporate vision, leading early-stage software venture capital funds. She was a founding member of BackWeb Technologies (NASD: BWEB), and began her career as a network engineer for the US and European governments.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Social Determinants of Health Data Evolution: Improve Access, Adherence and Achieve More Equitable Outcomes
Webcasts
Webinar Date/Time: Tue, May 16, 2023 2:00 PM EDT
Up to 80% of people’s health outcomes are influenced by non-clinical factors, however, most life sciences organizations lack a way of quantifying and understanding how they impact patient outcomes. Join industry leaders for a webinar to learn more about resources to help life sciences organizations better understand risk exposure for the communities and patients they serve.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
Event Overview:
Up to 80% of people’s health outcomes are influenced by non-clinical factors such as economic
strain, food insecurity, health literacy, transportation barriers. These non-clinical factors can
dramatically impact areas like disease and treatment awareness, medication adherence, clinical
trial recruitment and more. Most life sciences organizations lack a way of quantifying and
understanding the wide array of factors beyond clinical care impacting patient outcomes.
Traditional social determinants of health (SDOH) data points alone do not provide the insights to
develop a clear, actionable patient profile to achieve equitable care.
Join industry leaders for a webinar to:
Key Learning Objectives:
Who Should Attend:
Life Sciences Companies
Titles: Market Access, Payer Strategy, Access Strategy, Market Insights, Reimbursement, RWE, brand marketing, brand development, brand strategy, brand product marketing, commercialization, marketing and communications, analytics, health equity, HEOR
Speakers
Trenor Williams, MD
Co-founder and CEO
Socially Determined
Dr. Trenor Williams is a family physician, entrepreneur, former health system executive and consulting leader, past founder and CEO of Clinovations which he sold to the Advisory Board Company in 2014, and current CEO and CO-founder of Socially Determined. In 2017, Dr. Williams co-founded Socially Determined in order to create an analytics platform that integrates the social determinants of health with clinical and claims data in order to quantify and visualize social risk and the specific impacts on health and healthcare outcomes. With more than 20 years of healthcare experience, Dr. Williams’ unique perspective is formed at the intersection of healthcare and technology. He has an extensive understanding and knowledge in the implementation of healthcare technology, health plan market growth and SDOH strategy development for leading healthcare stakeholders here in the United States and around the world.
Mikki Nasch
Co-founder
Evidation Health
Mikki Nasch is focused on working to improve the patient experience. She is the former co-founder and head of business development at Evidation Health. Prior to Evidation, Mikki co-founded and led business activities at The Activity Exchange. Previously, Mikki was on the founding team of Sense Networks (exited to YP.com) and served as EVP of Business Development. Mikki has been the Vice President of Market Management at FairIsaac, Inc. (NYSE: FIC), held leadership positions in the incubation phase of numerous startups, and led development of products, sales strategies, business models and corporate vision, leading early-stage software venture capital funds. She was a founding member of BackWeb Technologies (NASD: BWEB), and began her career as a network engineer for the US and European governments.
Register Free: https://www.pharmexec.com/pe_w/social-determinants
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Biopharma Needs a Health System Strategy to Secure Optimal Market Access
In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.
‘Selling a Vision’: Today’s Playbook for Startups
The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Amazon Targeting the Transactional in the Pharma Market
A value deficit and potential consumer value proposition.
Study: Over 40% of Irritable Bowel Disease Patients Struggle to Afford Proper Healthcare
A new study found that among 2,200 patients with irritable bowel diseases, 63% encountered financial barriers that led to missed doses of medication.
Delivery and Disruption: Navigating a Changing Care Terrain
The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Biopharma Needs a Health System Strategy to Secure Optimal Market Access
In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.
‘Selling a Vision’: Today’s Playbook for Startups
The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Amazon Targeting the Transactional in the Pharma Market
A value deficit and potential consumer value proposition.
Study: Over 40% of Irritable Bowel Disease Patients Struggle to Afford Proper Healthcare
A new study found that among 2,200 patients with irritable bowel diseases, 63% encountered financial barriers that led to missed doses of medication.
Delivery and Disruption: Navigating a Changing Care Terrain
The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.